Immunecheckpoint blockage - a promising strategy to overcome glioma stem cell therapy-resistance

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Neurosurgery

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.21767/2471-9633.10001
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies

  2015cited by this paper
• Radiosensitization of Primary Human Glioblastoma Stem-like Cells with Low-Dose AKT Inhibition

  2015cited by this paper
• Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites

  2015cited by this paper
• CD133+ and Nestin+ Glioma Stem-Like Cells Reside Around CD31+ Arterioles in Niches that Express SDF-1α, CXCR4, Osteopontin and Cathepsin K

  2015cited by this paper
• New approaches for cancer immunotherapy

  2015cited by this paper
• Current challenges in designing GBM trials for immunotherapy

  2015cited by this paper
• The DNA damage/repair cascade in glioblastoma cell lines after chemotherapeutic agent treatment

  2015cited by this paper
• Immunotherapy for malignant gliomas.

  2015cited by this paper
• Stem cell signature in glioblastoma: therapeutic development for a moving target.

  2015cited by this paper
• 143 The Combination of anti-TIM-3 and anti-PD-1 Checkpoint Inhibitors With Focused Radiation Resulted in a Synergistic Antitumor Immune Response in a Preclinical Glioma Model

  2015cited by this paper
• FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas.

  2015cited by this paper
• Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status

  2015cited by this paper
• Radiation therapy for glioma stem cells.

  2015cited by this paper
• The PD-1/B7-H1 Pathway Modulates the Natural Killer Cells versus Mouse Glioma Stem Cells

  2015cited by this paper
• Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model

  2014cited by this paper
• CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy

  2014cited by this paper
• Oncogenic Signaling Is Dominant to Cell of Origin and Dictates Astrocytic or Oligodendroglial Tumor Development from Oligodendrocyte Precursor Cells

  2014cited by this paper
• Interleukin‐17 Facilitates the Immune Suppressor Capacity of High‐Grade Glioma‐Derived CD4 (+) CD25 (+) Foxp3 (+) T Cells Via Releasing Transforming Growth Factor Beta

  2014cited by this paper
• Detoxification of oxidative stress in glioma stem cells: Mechanism, clinical relevance, and therapeutic development

  2014cited by this paper
• Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors

  2014cited by this paper
• JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression.

  2014cited by this paper
• Heparan sulfate in the regulation of neural differentiation and glioma development

  2014cited by this paper
• Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell–mediated glioma rejection

  2013cited by this paper
• Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.

  2013cited by this paper
• Targeting Tregs in Malignant Brain Cancer: Overcoming IDO

  2013cited by this paper
• Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level.

  2013cited by this paper
• Monitoring of Regulatory T Cell Frequencies and Expression of CTLA-4 on T Cells, before and after DC Vaccination, Can Predict Survival in GBM Patients

  2012cited by this paper
• A restricted cell population propagates glioblastoma growth after chemotherapy

  2012cited by this paper
• Sequential Immunotherapy by Vaccination With GM-CSF–expressing Glioma Cells and CTLA-4 Blockade Effectively Treats Established Murine Intracranial Tumors

  2012cited by this paper
• Cancer stem cells and malignant gliomas. From pathophysiology to targeted molecular therapy.

  2011cited by this paper
• Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin.

  2010cited by this paper
• Glioma-Associated Cancer-Initiating Cells Induce Immunosuppression

  2010cited by this paper
• Glioma cancer stem cells induce immunosuppressive macrophages/microglia.

  2010cited by this paper
• Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions.

  2010cited by this paper
• CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo

  2007cited by this paper
• Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function

  2007cited by this paper
• An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme.

  2006cited by this paper
• Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors.

  2006cited by this paper
• Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

  2005cited by this paper
• Human Leukocyte Antigen and Antigen Processing Machinery Component Defects in Astrocytic Tumors

  2005cited by this paper
• Cancer stem cells in nervous system tumors

  2004cited by this paper

• Insights into molecular therapy of glioma: current challenges and next generation blueprint

  2017cites this paper
• The Kynurenine Pathway: A Primary Resistance Mechanism in Patients with Glioblastoma.

  2017cites this paper
• Linarin sensitizes tumor necrosis factor-related apoptosis (TRAIL)-induced ligand-triggered apoptosis in human glioma cells and in xenograft nude mice.

  2017cites this paper
• Recent advances and future of immunotherapy for glioblastoma

  2016cites this paper